Vision

“We are enhancing quality of life by providing ground-breaking therapies.”

History

TOPADUR Pharma AG was founded in 2015 by R&D experts with significant experience in pharmaceutical industry.

2023

January

February

March

April

May

June

July

August

September

October

November

December

2022

January

February

March

The European Patent Office granted a patent covering TOP-N53 used for the treatment of chronic wounds.

‍

April

Innosuisse grant awarded

‍

May

Innosuisse grant awarded

‍

June

July

August

September

TOP 100 Scale-ups 2022

‍

October

November

December

2021

January

Innosuisse grant awarded

‍

February

March

April

May

June

July

Submission to EMA of Orphan Drug Designation application for TOP-N53

Completion of TOP-N53 First-in-Man Study

August

September

October

Positive results from TOP-N53 FIH study

EMA granted TOP-N53 ODD for the treatment of Digital ulcers in Systemic sclerosis

‍

November

December

2020

January

February

March

April

May

Filing of fourth patent

June

July

Dr. Daniel Vasella; new Board Member

‍

August

September

Dosing of First Healthy Subjects in Phase 1 Clinical Study of TOP-N53
Top100 Swiss Startups 2020

October

November

December

2019

January

February

March

Filing of third patent

April

May

Innosuisse grant awarded

June

July

August

September

Winner of the 6th Dong Sheng Entrepreneurs Cup in Beijing, China
Top100 Swiss Startups 2019

October

November

Winner of the Young Entrepreneur Award

December

2018

January

February

March

April

May

June

July

August

Winner Swiss Innovation Challenge 2018

September

Successful Series B Financial Round
Top100 Swiss Startups 2018

October

Innosuisse grant awarded

November

Winner of the prestigious Swiss Economic Award 2018

December

2017

January

CTI grant awarded

February

March

April

Filing of second patent

May

June

July

August

September

Top100 Swiss Startups 2017

October

November

December

2016

January

EUROSTARS grant awarded

February

March

CTI grant awarded

April

Successful Series A Financial Round

May

June

CTI Certification

July

August

Winner Venture Leaders Life Science 2016

September

Top 100 Swiss Startups 2016

October

November

December

Winner IMD Startup 2016

2015

January

February

March

Foundation Topadur Pharma AG

April

Technical Closing Seed funding

May

June

Co-Winner Pitching Battle CEO day 2015

July

Coaching Acceptance granted by CTI Committee

August

September

October

November

Filing of first patent for TOP-N53

December

Headquarters / Labs established in Schlieren, Switzerland
Finalist Swiss Innovation Challenge 2015

2009-2015

January

February

March

April

May

June

July

August

September

October

November

December

Experimental research phase

2009

January

February

March

April

May

June

July

August

September

October

November

December

Foundation TOPADUR GmbH

Leadership

TOPADUR Pharma AG is built on a Leadership Team.

Pascal Brenneisen

Chief Executive Officer

Pascal Brenneisen, Entrepreneur & Chief Executive Officer of TOPADUR Pharma AG has over 30 years of management experience in the pharmaceutical & life science industry. Co-Founder & Board Member of several startup-companies, Pascal holds a master’s degree in law from the University of Basel and accomplished several Executive Educations at Harvard, Stanford and IMD.

Dr. Hermann Tenor

Chief Scientific Officer

Hermann Tenor is the Chief Scientific Officer and accumulated 24 years of industrial drug discovery and development experience. He was involved in the non-clinical characterization of a first-in-class marketed product. He is co-author on 50 scientific publications. Dr. Tenor holds an MD from the Martin-Luther University Halle Wittenberg.

Christina Attaalla

Chief Financial Officer

Christina Attaalla is the Chief Financial Officer and has 25 years of leading roles in finance, HR and administration heading groups of up to 20 employees and was executive board member for several SMES. She holds a BA in business administration from AKAD Zurich.

Dr. Christian Ludin

Chief Development Officer | Head of Legal

Christian Ludin has more than 20 years of experience in preclinical and clinical drug development. Dr. Ludin is an author and co-inventor of 13 patents and 15 publications and made significant contributions to the development of several preclinical and clinical candidates. He holds a PhD in Chemistry from the University of Freiburg i. Breisgau and an LLM in Law from the Faculty of Law at the University of Zurich.

Board of Directors

Dr. Reto Naef

Member since 2015

Prime Force consultant for scientific affairs, Novartis.
February 2015 – Now
CEO & Founder TOPADUR Pharma.
2015 – 2023
Head Research Operations Switzerland, Novartis.
January 2004 – February 2010

Prof. Dr. Günther Wess

Member since 2015

Chairman, Aventis Foundation.
Former Director of the Helmholtz Center in Munich till 2018.
Cardiovascular diseases, Diabetes and oncology, Former Europe Head Research Höchst, Aventis.